{
  "id": 10808409,
  "title": "Provisional extracellular matrix signaling network regulates tumor lymphoneogenesis and response to immunotherapy",
  "url": "https://urgent.news/2026/09/29/provisional-extracellular-matrix-signaling-network-regulates-tumor",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.24.753585v1?rss=1"
  },
  "original_language": "en",
  "account": "Therapeutic activation of tumor tertiary lymphoid structures (TLS) remains an ongoing challenge. Research has shown that proteolysis of the proteoglycan versican (VCAN) in tumor tissues is associated with increased T-cell inflammation and tumor T-cell infiltration. A study on human metastatic colorectal cancer found that the rate of VCAN proteolysis prospectively predicted outcomes after checkpoint inhibition immunotherapy, with a 100% overall survival rate in the group with high VCAN proteolysis at a median follow-up of 4.1 years.\n\nThe study further reveals that VCAN proteolysis occurs in CXCL13-replete germinal center light zones of secondary lymphoid tissue, while inducible VCAN proteolysis is localized in CXCL13-rich tumor stromal niches. The VCAN matrikine, versikine, activates CD11b+ dendritic cells (DC) and expands cDC1, which organizes TLS-archetypal triad hubs. In cases where VCAN is depleted, versikine-conditioned DC engage progenitor-exhausted CD8+ T-cells (Tpex) and Tpex-supporting, Th1-polarized CD4+ follicular-helper T-cells. On the other hand, excess unproteolyzed VCAN promotes DC-Treg crosstalk and Tpex loss from dysfunctional triads.\n\nThe research suggests that therapeutic activation of versikine (mRNA/protein) can eradicate experimental tumors that exhibit a weak VCAN-proteolysis state, which is present in 60-73% of human colorectal cancers. This discovery highlights the co-option of a matrix-processing step from normal germinal center biology and wound-repair processes in tumor lymphoneogenesis, with both prognostic and therapeutic implications.",
  "summary": "Therapeutic induction of tumor tertiary lymphoid structures (TLS) represents an unmet need. ADAMTS-mediated proteolysis of the proteoglycan versican (VCAN), a cardinal provisional matrix modification in wound-healing, correlates with tumor T-cell inflammation. In human metastatic colorectal cancer, VCAN proteolysis prospectively predicted outcomes after checkpoint inhibition immunotherapy, with…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}